<DOC>
	<DOCNO>NCT02014441</DOCNO>
	<brief_summary>The primary objective estimate proportion participant detectable talimogene laherparepvec deoxyribonucleic acid ( DNA ) blood urine time administration talimogene laherparepvec within first 3 cycle .</brief_summary>
	<brief_title>Single-arm Trial Evaluate Biodistribution Shedding Talimogene Laherparepvec</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Key Male female age ≥ 18 year histologically confirm diagnosis melanoma unresected stage IIIB , IIIC , IVM1a , IVM1b , IVM1c regardless prior line therapy . Subject candidate intralesional therapy administration cutaneous , subcutaneous , nodal disease must also measurable disease , serum lactate dehydrogenase ≤ 1.5 x upper limit normal , Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , adequate hematologic , hepatic , renal organ function . Key Subject must clinically active cerebral metastasis , great 3 visceral metastasis ( include lung metastasis nodal metastasis associated visceral organ ) bone metastases melanoma , primary ocular mucosal melanoma , history evidence symptomatic autoimmune pneumonitis , glomerulonephritis , vasculitis , symptomatic autoimmune disease , evidence immunosuppression reason . Subject know acute chronic active hepatitis B hepatitis C infection , human immunodeficiency virus infection also exclude . Subject active herpetic skin lesion prior complication herpes simplex virus type 1 ( HSV1 ) infection ( eg , herpetic keratitis encephalitis ) , and/or require intermittent chronic systemic ( intravenous oral ) treatment antiherpetic drug ( eg , acyclovir ) , intermittent topical use also excuded . Subject must receive previous treatment talimogene laherparepvec .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>